 

Call for proposals 2023

Research targeting development of innovative therapeutic strategies in cardiovascular disease (CARDINNOV)

**Call Text**

DEADLINES

February 7, 2023 (16:00, CET) - SUBMISSION OF PRE-PROPOSALS

June 15, 2023 (16:00, CEST) - SUBMISSION OF INVITED FULL-PROPOSALS

Link to electronic proposal submission

<https://ptoutline.eu/app/era4healthcvd>

For further information, please visit us on the website: <https://era4health.eu/>

or contact the Joint Call Secretariat (JCS):

French National Research Agency

Dr. Séverine Olivier and Dr. Martine Batoux

+33 1 73 54 81 74/+33 1 73 54 81 40

era4healthcall@agencerecherche.fr

Content

[Aim and ambition of ERA4Health 3](#_Toc121313498)

[Rationale 4](#_Toc121313499)

[Aim of the call 4](#_Toc121313500)

[General conditions for application 6](#_Toc121313501)

[Participating countries and respective funding organisations 7](#_Toc121313502)

[Application 8](#_Toc121313503)

[ELIGIBILITY CRITERIA 8](#_Toc121313504)

[Size of the consortium 8](#_Toc121313505)

[Financial and legal modalities 9](#_Toc121313506)

[Submission of joint proposals 9](#_Toc121313507)

[Further information 10](#_Toc121313508)

[Evaluation and decision 10](#_Toc121313509)

[Eligibility check and evaluation procedure 10](#_Toc121313510)

[Formal check and evaluation of pre-proposals 10](#_Toc121313511)

[Formal check and evaluation of full proposals. 11](#_Toc121313512)

[Evaluation Criteria 11](#_Toc121313513)

[Scoring system 12](#_Toc121313514)

[Rebuttal stage 13](#_Toc121313515)

[PRP meeting 13](#_Toc121313516)

[Ethical clearance 13](#_Toc121313517)

[Decision 13](#_Toc121313518)

[Redress procedure 14](#_Toc121313519)

[Responsibilities, Reporting requirements and Dissemination 14](#_Toc121313520)

[Consortium Agreement 14](#_Toc121313521)

[Open Science 15](#_Toc121313522)

[Progress report 15](#_Toc121313523)

[Communication 15](#_Toc121313524)

[Support for Early Career Scientists 16](#_Toc121313525)

[Confidentiality 16](#_Toc121313526)

[General Data Protection Regulation 16](#_Toc121313527)

[ANNEX I 18](#_Toc121313528)

# Aim and ambition of ERA4Health

The Partnership “Fostering a European Research Area for Health” (ERA4Health) aims at establishing a flexible and effective coordination between funding organisations in the European Research Area (ERA) for Health and Well-being. This Partnership brings the opportunity to increase European transnational collaborative research funding by creating a funding body for joint programming in priority areas addressing European Public Health Needs.

The general objective of ERA4Health is to reach an effective joint approach and generate knowledge and products (e.g. preventive guidelines, medical protocols) in the identified research areas as outlined in ERA4healthStrategic Research and Innovation Agenda (SRIA)[[1]](#footnote-2). To achieve this, a comprehensive network will be created which aims at strengthening and expanding the existing conducive eco-system.

In this light, ERA4Health gathers public funders of health research in the European Research Area including the European Commission that jointly identify and implement a common funding strategy in priority areas to advance health research and develop innovation.

ERA4Health has 4 specific objectives:

* SO1. Support relevant medical research including clinical fields and intervention areas (prevention, diagnosis, treatment),
* SO2. Improve the utilisation of existing health technologies in clinical practice,
* SO3. Build capacity, in particular in conducting IICSs at European scale,
* SO4. Implement and advance the practice of Responsible Research and Innovation (RRI) across the breadth of the programme.

# Rationale

Cardiovascular disease is the main cause of death worldwide leading to 17.9 million deaths per year representing 32% of global deaths[[2]](#footnote-3). In Europe, cardiovascular disease cause over 3.9 million deaths per year, which represents 45% of total deaths and an economic cost of €210 billion a year[[3]](#footnote-4). Cardiovascular diseases, that cover a broad range of conditions affecting the heart and blood vessels, is also expected to remain the largest cause of death over the next 20 years. In addition, our understanding of, and ability to prevent or treat, the less common forms of cardiovascular diseases are still very limited.

Advances in therapeutic solutions are currently stagnating since there are limited studies that test newly discovered, non-redundant and critical disease-causing or aggravating pathways. There is thus a specific need of new concepts for tailored treatments of cardiovascular diseases. In particular, future research should pursue translational studies with a focus on discovering new pathophysiological pathways underlying chronic cardiovascular disease with a high societal impact.

Research and engineering that build our understanding of molecular and cellular mechanisms governing cardiovascular development as well as physiological and pathological signaling through an integrative approach will allow the development of new strategies to foster reparation and/or regeneration of the heart and/or the blood vessels, that will be useful for the treatment of cardiovascular disease. Among these, heart failure and atrial fibrillation are a leading cause of cardiovascular morbidity and mortality. Since cardiovascular disease has become chronic in nature, this, in combination with aging of the population across Europe and occurrence of co-morbidity factors, will result in an increase in the prevalence of heart failure and atrial fibrillation. Thus, the development of innovative strategies targeting the responsible pathophysiological mechanisms and, taking into account co-morbidity factors, is necessary for the treatment of chronic heart failure (especially with preserved ejection fraction) and atrial fibrillation. The development or the optimisation of new treatment modalities and strategies more effective and less costly for society will contribute to healthy ageing of present and future populations and to a better economy.

The aim of this call is to enable scientists in different countries to build a valuable collaboration on common interdisciplinary research projects based on complementarities and sharing of expertise in the field of cardiovascular disease treatments with a clear translational research approach. In-depth, two-way engagement with different actors from academia, healthcare providers, industry, as well as patients’ organizations will help to develop effective research strategies. This call promotes cooperation at transnational level and will open the way for new therapeutic strategies for patients in Europe and worldwide.

# Aim of the call

Proposals must present research that addresses one or both of the following topics:

1) Repair and/or regeneration of the heart and/or the blood vessels

The proposals should focus on:

* The identification of integrative approach, clinically relevant, based on molecular and cellular levels and/or the link between these two levels. Poorly known mechanisms should be the focus of the proposal e.g. (but not limited to) the inflammatory reaction, the amyloid accumulation, endogenous mechanisms of repair, linked to thromboembolism and/or related to macrovascular compartment and autonomous nervous system.
* And/or the development of cell and non-cell-based approaches in combination with bioactive biomaterials/ bioengineered patches or grafts.

2) Chronic heart failure and atrial fibrillation

The proposals should focus on the development of treatment strategies that can reverse the pathophysiology responsible for chronic heart failure (especially with preserved ejection fraction), atrial fibrillation and/or the both diseases. The therapeutic strategies should take into account patient comorbidities and their potential treatment.

Exclusion:

For both topics, research on cell therapy is strictly restricted to novel and innovative approaches.

Beyond the research topics the following points should be taken into account, including approaches to responsible research and innovation:

* + Proposals must clearly demonstrate the potential health impact and/or economic impact as well as the added-value of transnational collaboration: sharing of expertise and resources (models, databases...), harmonization of data, access to innovative technologies, etc.
	+ Proposals should clearly promote translational research and demonstrate the benefit of working together and the unique contribution of each partner.
	+ Studies on human biological material or using data existing in databases from completed clinical studies (including bioinformatics and personalized medicine concepts) are mandatory as research should be oriented to clinical research to ensure an efficient transfer from bench to bedside. Furthermore, in the framework of this call small-scale clinical studies (up to phase 2) are allowed. *In vitro* (e.g. human cells), *in silico* (e.g. bioinformatics) and animal (e.g. small or large animals) studies can also be included in a same proposal if they have a clear relevance to human health. In the proposal, the use of any animal models must be justified and it must be substantiated why *in vitro* or *in silico* studies cannot provide solutions.
	+ Except for small-scale clinical studies up to phase 2, the start of other clinical studies is excluded in this call.
	+ Proposals are strongly encouraged to engage end-users (e.g. patients, industry, clinicians) in the research process from conception of the study to dissemination and implementation. End-users can participate as partners (when eligible for funding by a national/regional funding organisation), as collaborator (participation with own budget) or as part of an advisory board.
	+ Proposals should consider potential moderators of effects such as age, sex, gender and ethnic or other demographic features/differences in the respective research approaches.
	+ The use of approaches from precision medicine, personalized medicine and nanomedicine are encouraged.
	+ Proposals should make use of existing biobanks and existing cohorts, if applicable. Otherwise, it should be explained why existing biobanks/ cohorts are not used.
	+ The consortia are encouraged to consider the gender balance in the composition of the consortia and to balance the responsibilities between them.
	+ Early Career Scientists (Master, PhD and post-docs) are encouraged to participate in the consortium.

# General conditions for application

The duration of the projects will be 36 months.

Proposals **must clearly demonstrate the potential health,** **economic, and/or policy impacts,** as well as **the added-value of transnational collaboration** i.e. sharing of resources (models, registries, diagnosis, etc.), harmonisation of data, sharing of specific know-how and/or innovative technologies.

**Proposals should follow the principles of Responsible Research and Innovation (RRI). All consortia should** demonstrate a commitment for investigating and addressing social, ethical, political, environmental or cultural dimensions of the proposed research. The proposal template further elaborates on this and how RRI dimensions can be approached.

Research supported by ERA4Health must respect fundamental ethical principles. Applicants have to describe any potential ethical aspects of the work to be carried out, and how the project will fulfil applicable requirements in institutional, national and European Union legislation (including the ethical standards and guidelines of Horizon 2020/Europe[[4]](#footnote-5)).

The individual project partners of the joint applications should be complementary and the proposed work should contain novel, innovative and ambitious ideas with a high application potential for the end-users and/or with a high implementation potential to benefit of end-users/patients/citizens.

Furthermore, additional elements need to be considered in the application:

* If appropriate: the design of the study (sample collection, statistical power, interpretation, relevant models for hypothesis validation) must be well justified and should be part of the proposal.
* For small-scale clinical studies up to phase 2: strategies for recruitment, retention, assessment, and analysis must be included. The study design and objectives should take into consideration the population that would be needed to reach the objective of the study. Data supporting the recruitment numbers is recommended.
* In case of an exploratory animal/ small-scale clinical study up to phase 2, a detailed description is required as part of the full proposal application form (requirements are included in the Guidelines for Pre-clinical and small-scale clinical studies up to phase 2). The review panel will scrutinize this information as part of the formal evaluation criteria (1-Excellence) of full proposals. Assistance for provision of the information on experimental design can be found in the general [ARRIVE guidelines](https://journals.plos.org/plosbiology/article/file?id=10.1371/journal.pbio.1000412&type=printable)[[5]](#footnote-6).

# Participating countries and respective funding organisations

The following participating funding organisations have agreed to fund this call for transnational research projects:

|  |  |  |  |
| --- | --- | --- | --- |
| **Countries** | **Funding organisations** | **Acronym** | **Contribution (€)** |
| Austrian | Austrian Science Fund | FWF | 2 000 000  |
| Belgium | Fund for Scientific Research-FNRS | F.R.S.-FNRS | 300 000  |
| Belgium | The Research Foundation - Flanders | FWO | 700 000  |
| France | French Research Funding Agency | ANR | 2 500 000  |
| Israel | Ministry of Health | CSO-MOH | 320 000 |
| Italy | Ministry of Health | IT MOH | 1 500 000  |
| Italy | Italian Ministry of Universities and Research | MUR | 1 000 000  |
| Latvia | Latvian Council of Science | LCS | 500 000  |
| Lithuania | Research Council of Lithuania | LMT | 200 000  |
| Poland | National Centre for Research and Development | NCBR | 1 250 000  |
| Portugal | Foundation for Science and Technology  | FCT | 250 000  |
| Romania | Executive Agency for Higher Education, Research, Development and Innovation Funding | UEFISCDI | 1 000 000  |
| Slovakia | Slovak Academy of Sciences | SAS | 240 000 |
| Spain | State Research Agency  | AEI | 1 000 000  |
| Spain | Regional Ministry of Health and Consumer Affairs of Andalusia | CSCJA | 250 000  |
| Spain | Institute of Health Carlos III | ISCIII | 1 600 000  |
| Taiwan | National Science and Technology Council | NSTC | 810 000  |
| The Netherlands | Dutch Research Council | NWO | 2 700 000 |
| Turkey | The scientific and technological research council of Turkey | TUBITAK | 750 000 |

*Table 1: Participating funding organisations*

Project partners will be funded by their relevant national/regional funding organisations. Eligible costs and funding rules vary between the respective funding organisations (see Annex I).

# Application

## ELIGIBILITY CRITERIA

Joint research proposals may be submitted by applicants belonging to one of the following categories (according to national/regional regulations; certain categories may not be eligible for funding by a specific funding organisation, please see Annex I):

* **A. Academia –** research teams working in universities, other higher education institutions or research institutes.
* **B. Clinical/public health sector –** research teams working in hospitals/public health and/or other health care settings and health organisations.
* **C. Enterprises** **–** private companies of all sizes.
* and **D. Operational stakeholders** **–** e.g. patient advocacy organisations, municipalities and local governments, local/national NGO’s. In line with the concept of RRI, operational stakeholders should be in a position to provide useful knowledge to the consortium, ensure the consortium’s research is useful and translatable to their (or other) organizational contexts, and/or influence decision making or create change within their organisations. Operational stakeholders should be engaged in the research process from conception of the study to dissemination.

### Size of the consortium

The number of participants and their research contribution should be appropriate for the aims of the transnational research project and be reasonably balanced in terms of international participation. Each transnational collaborative project should represent the critical mass to achieve ambitious scientific goals and should clearly demonstrate an added value from working together.

Only transnational projects will be funded. The following conditions apply to the composition of consortia:

* Minimum of three eligible and a maximum of five eligible partners from at least three different countries participating in the call (see list above).
* The maximum number of eligible partners can be increased up to six or seven (see table below) if they include one or two partners, respectively, from the following participating countries: Latvia, Lithuania, Romania, Slovakia, Turkey.
* No more than two eligible partners from the same country participating in the call will be accepted within one consortium.
* Maximum of two collaborators per consortium. Collaborators are self-funded partners: i.e. partners that do not request funds in this Joint Transnational Call provided by one of the participating funding organisations (i.e. partners from non-funding countries or partners which are not fundable according to national/regional regulations of the participating funding organisations).

The following conditions apply for collaborators:

* + Clear added value for the research project. This should be demonstrated in the application.
	+ Secure own funding for participation with clear evidence in the proposal that this is already in place.
	+ A letter of commitment of the collaborator(s) needs to be included as an annex to the pre-proposal/ full proposal.
	+ A collaborator cannot be work package leader.

|  |  |  |  |
| --- | --- | --- | --- |
| Number of partners requesting funding (eligible partners) | **3-5** | **6**  | **7**  |
| Partners from underrepresented countries | No constraints | At least 1 | At least 2 |
| Maximum number of collaborators | 2 | 2 | 2 |

*Table 2: Possible composition of a research consortium*

Each project consortium must nominate **a project coordinator** from the participating principal investigators (NOT a collaborator). The project coordinator will represent the consortium externally and will act as contact person for the Joint Call Secretariat (JCS) and will be responsible during the entire process for the internal scientific management such as controlling, overseeing IPR issues, reporting, and contact with the JCS.

Each principal investigator can submit only **one proposal as project coordinator or up to two proposals as mere partner** (i.e. the coordinator of a proposal cannot be partner in another proposal) Please note that this rule may be subject to national/regional regulations. Applicants are consequently strongly encouraged to contact their national/regional contact points to check their national/regional eligibility rules before submission (see Annex I).

**The partner search tool** of the European Commission[[6]](#footnote-7) can be used to offer your support or look for a partner (Topic: HORIZON-HLTH-2022-DISEASE-03-01).

### Financial and legal modalities

Project partners will be funded by their relevant national/regional funding organisation. Eligible costs, funding rules and the type of studies allowed vary between the respective funding organisations (see Annex I). Each project partner must be involved in the budgeting of their planned tasks.

For information on the specific funding rules and eligibility criteria of the national/regional funding organization

* Carefully read Annex I and the national/regional announcements of the call
* In addition, applicants are strongly advised to contact their relevant funding organisation contact person before submitting an application; please note that for some countries/regions it might be mandatory.

Please note that if a partner is found to be non-eligible at any step of the process by one of the funding organisations, the entire proposal could be rejected without further review.

## Submission of joint proposals

There will be a two-step submission and evaluation procedure for joint applications, i.e. pre-proposals and full proposals, and the full proposal review process will be complemented by a rebuttal stage. For both submission steps, one joint proposal document (in English) shall be prepared by the partners of a joint transnational proposal and must be submitted to the JCS by uploading it on the electronic [submission system](https://ptoutline.eu/app/era4healthcvd) by the project coordinator. The two-step application process will have the following timeline:

|  |  |
| --- | --- |
| **7 December, 2022** | **Publication of CARDINNOV call** |
| **7 February, 2023, 16h00 CET** | **Deadline for pre-proposal submission** |
| 28 April, 2023 | Communication of the results of the pre-proposal assessment (invitation for full proposal) |
| **15 June, 2023, 16h00 CEST** | **Deadline for full proposal submission** |
| **29 August – 6 September, 2023** | **Rebuttal stage** |
| End of October | Communication of the funding decisions to the applicants |
| **December 2023 – May 2024** | **Expected project start** (subject to national procedures) |

Table 1: Timeline application process

The pre-proposal template will be available on the ERA4Health website (https://era4health.eu/first-call/).

An application template for the full proposal stage will be sent to the project coordinator by the JCS with the invitation to submit a full proposal.

Pre-proposals or full proposals submitted without using the relevant template will be declared non-eligible.

If applicable, a proposal should be submitted together with a legal/ethical approval document according to the concerned country’s/region’s regulations.

For applicants from specific countries/regions it might be mandatory to submit the additional national/regional proposal and/or other information, in some cases before the deadline of this call, directly to the national/regional funding organisations. Therefore, applicants are strongly advised to check their funding organisations specific regulations. See Annex I for more details.

The CSC will take all lawful steps to ensure confidentiality of the information and documents obtained during the evaluation and selection procedure of the joint call.

## Further information

For additional information, please contact the JCS, or your national/regional funding organisation Contact Person (see Annex I).

# Evaluation and decision

## Eligibility check and evaluation procedure

### Formal check and evaluation of pre-proposals

The JCS will check all proposals to ensure that they meet the call’s formal criteria (date of submission; number and category of participating countries; inclusion of all necessary information in English; appropriate limits on length). In parallel, the JCS will forward the proposals to the national/regional funding organisations, which will perform a check for compliance with national/regional regulations.

Each proposal passing the eligibility check (JCS and country/region) will be evaluated by three reviewers for a first evaluation (see evaluation criteria below). The reviewers will perform the assessment of the pre-proposal and complete a written evaluation form with scores and comments for each evaluation criterion. The consortia will receive the evaluation, and where necessary will include advice on their RRI approach. The CSC members will meet to decide which proposals will be invited to submit a full proposal based on the reviewers’ recommendations and to ensure a reasonable balance of requested and available national/regional budgets. Pre-proposals which do not pass this assessment will not be considered for the full proposal stage.

### Formal check and evaluation of full proposals.

The JCS will check the full proposals to ensure that they meet the call’s formal criteria and have not changed substantially from the respective pre-proposals before sending them to the reviewers. Any fundamental change between pre- and full proposals, e.g. concerning the composition of the consortium, the objectives of the project or the requested budget must be communicated to the JCS and to the national/regional involved funding organisations. In exceptional cases, these changes may be admitted if detailed justification is provided and if they are accepted by CSC.

Each full proposal will be allocated to three reviewers. The reviewers will perform the assessment of the full proposal and complete a written evaluation form with scores and comments for each criterion (see evaluation criteria below). During a Peer Review Panel (PRP) meeting, the reviewers will discuss all proposals and produce a ranking list of proposals recommended for funding.

Before the PRP members meet to discuss each **full proposal** in a PRP meeting, each coordinator is provided with the opportunity of getting acquainted with the assessments and commenting on the arguments and evaluations of the reviewers (see section “Rebuttal”).

## Evaluation Criteria

**1. Excellence**

a. Scientific quality of the proposal:

* Significance of the research question,
* Clarity and relevance of the objectives,
* Credibility and clarity of the proposed approach and methodology (including power calculations, randomisation, blinding and bias, target group(s) studied, as well as approach to responsible research and innovation),
* Expected progress beyond the state-of-the-art, clearly demonstrating an innovation potential,
* Quality of the project consortium: international competitiveness of participants in the field(s), previous work and specific expertise of the participants, complementarity of the participants, benefit of the transnational collaboration.

b. Novelty and ambition (including translatability of the proposed research to human health).

**2. Impact**

a. Unmet public and societal need and potential impact of the expected research results for future clinical, public health, and/or other socio-economic health relevant applications including patients’ needs and/or for industry (i.e. product development).

b. Added-value of transnational collaboration and potential for fostering international network: gathering a critical mass of patients, sharing of resources (biological material, models, databases, etc.), harmonization of data, sharing of specific know-how and/or innovative technologies, etc.

c. Projects with high potential of applicability at short/medium term: expected time for market and transfer to patient towards clinical and public health applications, pharmaceutical/health device applications, other industrial applications including market and end user’s scenario, quality of dissemination, exploitation and business plan. (when appropriate/applicable).

d. Participation/engagement with end-users such as patients, industry, clinicians (when appropriate/applicable).

e. Effectiveness of the proposed measures to exploit and disseminate the project results (including management of intellectual property rights), to communicate the project results in a tailored manner to the different audiences (e.g. policy makers, industry, patients), and to manage research data where relevant.

*Sub-criterion 2e will be evaluated at the full proposal evaluation stage.*

**3. Quality and efficiency of the implementation**

a. Feasibility of proposal and likelihood of successful completion of proposed research.

b. Coherence and effectiveness of the work plan (including appropriateness of the allocation of tasks, resources and timeframe).

c. Use of existing biobanks and existing cohorts (when appropriate/applicable).

d. Adequacy of the budget: appropriate distribution of resources in relation to project activities, partner’s responsibilities and time frame.

e. Appropriateness of the management structures and procedures, including risk, innovation management and RRI and ethical considerations.

f. Sustainability of the research capacities initiated by the project (e.g. FAIR data management, Open Science practices). Quality of the Intellectual Property management.

*Sub-criterion 3d, 3e and 3f will be evaluated at the full proposal evaluation stage.*

**Proposals not relevant to the call topic and objectives will not be funded, independently of their scientific quality.** Evaluation scores will be awarded for the three main criteria. Each criterion will be scored out of five.

## Scoring system

**5 = Excellent.** The proposal successfully addresses all aspects of the criterion in question.

**4 = Very good.** The proposal addresses the criterion very well, but small improvements are possible.

**3 = Good.** The proposal addresses the criterion in question well, but certain improvements are necessary

**2 = Fair.** The proposal generally addresses the criterion, but there are significant weaknesses that need corrections.

**1 = Poor.** The proposal shows serious weaknesses in relation to the criterion in question.

**0 = Failure.** The proposal fails to address the criterion in question or cannot be judged because of missing or incomplete information.

**A full proposal will be considered fundable if the threshold score for individual criterion is 3 points and the overall score at least 10 points.**

## Rebuttal stage

Before the PRP members meet to discuss the full proposals in a PRP meeting, each coordinator is provided with the reviewers’ assessments. This stage allows applicants to comment on factual errors or misunderstandings that may have occurred in the review process and to reply to reviewers’ questions. However, issues not related to reviewers’ comments or questions cannot be addressed and the work plan cannot be modified at this stage.

The applicants will have up to one week (29 August – 6 September, 2023) for this optional response to the reviewers’ comments. Answers sent after the notified deadline, or not related with reviewers’ comments or questions will be disregarded.

## PRP meeting

The JCS will give the PRP members access to full proposals, reviews and rebuttals, taking into consideration potential conflicts of interest. The PRP will meet to discuss each proposal and, after consideration of the evaluation criteria, external reviews, rebuttals, and their own reviews and discussions, the PRP will assign final scores, make a classification of the proposals, and rank proposals recommended for funding. The final summary review report prepared by the PRP members will be sent to the respective project coordinators.

## Ethical clearance

After the PRP meeting, members of the ERA4Health Ethics and RRI Advisory Board will remotely check the full proposals, which are recommended for funding by the PRP and selected for funding by the CSC, for alignment with ethical norms and regulations. If necessary, tasks that need to be performed and documents that need to be submitted by the consortium will be listed. The Ethics experts may put forward additional conditions that need to be fulfilled by applicants. Only those proposals approved by both the scientific evaluation and ethical assessment (complying with all central Horizon Europe and regional/national ethical requirements), will be funded.

## Decision

A final decision, based on the ranking list established by the PRP, available funding and the ethical clearance, will be taken by the national/regional funding organisations.

Project coordinators having submitted an eligible proposal will be informed about the funding recommendation regarding their proposal by the JCS. The projects coordinators are responsible to communicate this information to their project partners.

# Redress procedure

Applicants can appeal against the evaluation outcome if they suspect a breach in the application of the evaluation and selection procedures. This redress procedure only covers the procedural aspects of the evaluation and/or eligibility checks, including the national eligibility checks. The redress will not call into question the scientific or technical judgement of appropriately qualified experts.

In this case they shall submit their appeal to the JCS via email (era4healthcall@agencerecherche.fr), up to 7 calendar days after the date of dispatch of the evaluation outcome email by the call secretariat at the end of each stage (first or second step). The proposal outcome email containing the results of the evaluation will give information on the appeals procedure, which is described below.

**Admissibility of appeals**

For an appeal to be admissible the following conditions must be met:

- The appeal must be submitted by the coordinator of the proposal to which the appeal relates

- Only one appeal per proposal will be considered

- The appeal must be submitted via email within the 7 calendar days deadline. The appeal must contain the following minimum information:

* The name of the call for proposals;
* The proposal acronym;
* The title of the proposal;
* A description of the alleged shortcomings of the evaluation procedure.

The appeal must demonstrate a procedural irregularity, factual error, manifest error of assessment, misuse of powers, or a conflict of interests. Appeals that do not meet the above conditions, or do not deal with the evaluation of a specific proposal or express mere disagreement with the result or the reasoning of the evaluation might be judged as not suitable for redress.

**Procedure**

Upon receipt of an appeal, an acknowledgement of receipt will be sent by the call secretariat within 7 calendar days. The acknowledgement shall report the redress process and the anticipated date by which a decision on the appeal will be communicated to the appellant.

All appeals received by the 7 calendar days deadline will be processed together and the decision will be communicated to the appellant within 7 calendar days from the deadline for submitting the appeals.

# Responsibilities, Reporting requirements and Dissemination

## Consortium Agreement

It will be the responsibility of the project coordinator to draw up a Consortium Agreement (CA) suitable to the project partners in order to manage the delivery of the project activities, finances, intellectual property rights (IPR) and to avoid disputes which might be detrimental to the completion of the project. The project consortium is strongly encouraged to sign this CA before the official project start date, and in any case the CA should be signed in the first 6 months of the project**.** Please note that national regulations may apply concerning the requirement for a CA (e.g. certain funding organisations may need the signed CA to release some funds). Further instructions will be provided by the JCS to the coordinators of the projects selected for funding.

## Open Science

Importantly, all funding recipients must ensure that all outcomes (publications, etc.) of transnational ERA4Health-funded projects are published with Open Access. All research projects funded by ERA4Health are eligible to publish on **Open Research Europe (ORE)**, the [Platform of the EC](https://open-research-europe.ec.europa.eu/)[[7]](#footnote-8) at no cost.

The new research data resulting from the project should be treated according to the [FAIR](https://www.nature.com/articles/sdata201618)[[8]](#footnote-9) principles, and deposited and shared, according to the national rules of the countries involved. To make research data findable, accessible, interoperable and re-usable (FAIR), a Data Management strategy for the proposed full projects is mandatory in the second evaluation stage. Projects selected to receive funding in the current call, will be requested to present a more detailed Data Management Plan (DMP) before month 6 from the official start of the project and an update of the DMP will be asked at the end of the projects.

## Progress report

The project coordinator is required to submit an annual scientific progress report on behalf of the consortium to the JCS in March of each year, detailing how the project is progressing in relation to planned objectives. Furthermore, a final scientific report must be sent to the JCS within a period of two months after the project has ended. In addition to the reports, information related to some indicators related to the project may be collected on a platform/survey.

National funding organisations may also request financial and/or scientific annual progress reports and/or a final report on the project from the partners from their respective country.

In addition, the coordinators of each consortium may be asked to participate in a kick-off meeting and present two progress updates, one mid-term and one final status symposium. An appropriate travel budget should be included and justified in the financial plan for the proposal. In case some of the events are organised as an online conference, all partners of the consortia will be encouraged to participate.

## Communication

The project coordinator will represent the consortium externally and will be responsible for all communication with the relevant ERA4Health bodies. The coordinator must promptly inform the JCS in case of ANY significant changes in the work plan or the consortium’s composition. The JCS will inform the relevant funding organisations, who will decide upon the proper action to be taken.

Project coordinators, upon notification, are required to deliver an abstract of their project suitable for communication and dissemination purposes.

For the effective contribution of the project to the objectives of the ERA4Health, the project coordinator should be available to participate in meetings/workshops with the aim of:

* exchanging project results;
* developing a joint strategy to coordinate and facilitate integration of the planned activities of ERA4Health;
* communicating results across ERA4Health.

Importantly, all funding recipients must ensure that all outcomes (publications, etc.) of transnational ERA4Health funded projects include proper acknowledgement of the ERA4Health partnership and the respective funding partner organisations.

 “*This project received funding from [name of funding organisations, or an acknowledgment as requested by your national/regional funding organisations] under the umbrella of the Partnership Fostering a European Research Area for Health (ERA4Health) (GA N° 101095426 of the EU Horizon Europe Research and Innovation Programme).*”

## Support for Early Career Scientists

All project coordinators and other principal investigators are asked to encourage the Early Career Scientists that will be involved in the research projects to actively engage in an upcoming ERA4Health Early Career Network (ECN) by including travel costs for Early Career Scientists and by allowing to dedicate a small amount of their working time to the ECN. In addition, the research consortia are invited to include training activities for Early Career Scientists into their proposals. Examples of training activities are mobility and lab visits of ECSs between partners of the consortium or implementation of summer school(s).

# Confidentiality

The ERA4Health JCS takes all reasonable steps to ensure that information provided in the application is treated confidential.

The proposals will be handled confidentially by the JCS and by the national/regional funding organisations. In selecting the international experts for the PRP, the JCS shall endeavour to avoid any possible conflicts of interest (CoI).

Each expert will have to sign a declaration of confidentiality and absence of conflict of interest. In case of a CoI the reviewer will be withdrawn from evaluating the respective proposal.

# General Data Protection Regulation

The following Data Privacy Notice applies:

By submitting an application, the applicants consent to the use, processing and retention of their personal data[[9]](#footnote-10), in accordance with article 6.1 (e) and (c) of the General Data Protection Regulation (GDPR) (2016/679) and for the purposes of:

* processing and evaluating the application where processing shall be lawful only if and to the extent that processing is necessary for the performance of a task carried out in the public interest or in the exercise of official authority vested in the controller,
* administering any subsequent funding award,
* managing the funding organisations relationship with them,
* analysing and evaluating the call,
* providing aggregate data to national and European surveys and analyses on the funded projects,
* and complying with audits that may be initiated by the funding organisations and the European Commission (or its agencies).

The members of the CSC may share applicant’s data with third parties (some of which may be based outside the European Economic Area) in relation to the above activities including evaluators, auditors and the European Commission (or its agencies).

The members of the CSC may link the data that funding recipients provide in the application with national, bibliographic or external research funding data which are available through public subscription-based databases (e.g. Scopus, Web of Science, etc.) or other national / open datasets.

# ANNEX I

|  |  |
| --- | --- |
| **Country** | Austria |
| **Funding organisation** | Austrian Science Fund |
| **National contact person** | Markus KubicekT: +43 1 505 67 40 8202markus.kubicek@fwf.ac.atStefanie SchaggingerT: +43 1 505 67 40 8213stefanie.schagginger@fwf.ac.at  |
| **Funding commitment**  | € 2.000.000,00 |
| **Anticipated number of fundable proposals**  | The FWF anticipates funding of approximately four to six projects, given the maximum commitment of € 2 Mio for all projects |
| **Maximum/ Minimum funding per grant awarded to a project partner** | The FWF generally does not have any minimum or maximum limits but, given the limited nature of the financial commitment of the FWF to this Call (see above), we do expect Austrian participations not to exceed the average range of a typical FWF stand-alone Project (typically up to € 300.000 – 400.000 €). |
| **Eligibility of partners**  | Individual researcher or teams of researchers, working in any kind of non-profit organisation: e.g. University, University hospital, Non-university research institute. Please refer also to the general FWF Funding Guidelines: [p\_application-guidelines.pdf (fwf.ac.at)](https://www.fwf.ac.at/fileadmin/files/Dokumente/Antragstellung/Einzelprojekte/p_application-guidelines.pdf) also available on: [Joint Projects / ERA-Nets (fwf.ac.at)](https://www.fwf.ac.at/en/research-funding/application/international-programmes/joint-projects-era-nets/)  |
| **Eligibility of costs, types and their caps** | The current FWF salary scale([Personnel costs (fwf.ac.at)](https://www.fwf.ac.at/en/research-funding/personnel-costs) ) indicates the salaries that may be requested. The FWF grants an annual salary adjustment to compensate for inflation; this is applied automatically to all contracts of employment in stand-alone projects that are valid when the adjustment takes effect.For scientists funded by the FWF, the funding is limited to “project-specific costs, i.e. personnel and non-personnel costs that are essential to carry out the project and that go beyond the resources made available from the research institution’s infrastructure, according to the general FWF Funding Guidelines published at [p\_application-guidelines.pdf (fwf.ac.at)](https://www.fwf.ac.at/fileadmin/files/Dokumente/Antragstellung/Einzelprojekte/p_application-guidelines.pdf)The FWF does not finance infrastructure or basic equipment at research institutions. Overheads may not be requested. Subcontracts must be well justified, i.e. must represent the only or the most economical way to have the work performed, please contact the FWF directly for clarification of individual cases |
| **Submission of the proposal at the national level** | In addition to the application at the ERA4HEALTH level, administrative data (in accordance with the FWF guidelines for stand-alone projects) must be submitted online to the FWF at <https://elane.fwf.ac.at/> This is required already at the pre-proposal stage via the programme category “IK – International Projects (preproposal, deadline 7 February 2023For the full proposal stage applicants must choose theprogramme category “I – International Projects” (Deadline 15 June 2023. Both steps are mandatory.For submissions to be valid, the cover sheet generated at the end of the online submission process must be printed out and signed. It can then either be sent to the FWF by conventional mail (FWF, Sensengasse 1, 1090 Vienna) or scanned in, given a digital signature and sent to the FWF (office@fwf.ac.at ) as an e-mail attachment. Please note that the number of ongoing/approved projects in which one researcher can serve as principal investigator is limited to three in the Stand-Alone Projects Programme, International Programmes, Clinical Research and Arts-Based Research Programmes. Information on the limit of the number of ongoing/approved projects and thus the limit of applications that can be submitted can be found at [project\_number\_limit.pdf (fwf.ac.at)](https://www.fwf.ac.at/fileadmin/files/Dokumente/Antragstellung/project_number_limit.pdf) For information on submitting an application from abroad see the FWF Website at [Applications from abroad (fwf.ac.at)](https://www.fwf.ac.at/en/research-funding/applications-from-abroad/) |
| **Submission of other information at the national level** | See above |
| **Submission of financial and scientific reports at the national level** | Not applicable |
| **Further guidance** | Researchers are eligible to apply if their publication record over the last five years has been internationally visible and if their current career stage is commensurate with the career progression expected in their field. The following criteria are decisive in assessing their publication record—documented in the “Publication list” and in initiating the review process: **Quality assurance:** Most relevant in assessing the applicant’s publication record are those publications that have undergone a quality assurance procedure in line with international standards (peer reviewor an equivalent procedure; in the natural and life sciences, peer reviewis expected). Journals must usually be listed in Web of Science, Scopus, or the Directory of Open Access Journals (DOAJ). In the case of journals that are not listed in these databases, or in the case of monographs, edited volumes, contributions to edited volumes, or other publication types, the applicant must provide a link to the publisher’s website, describing the respective quality assurance procedure. If no description should be available, it is the applicant’s responsibility to provide evidence that the publication has been subject to an appropriate quality assurance procedure.**International visibility:** Most of the applicant’s publications must have a wider than national reach. In the natural sciences, life sciences, and social sciences, most of the publications listed must be in English.**Number/scope and quality** of the applicant’s publications must be commensurate with the expected career progression and the field concerned. At least two publications must have undergone a quality assurance procedure and must be internationally visible with a substantial and independent contribution on the part of the applicant. At least one publication with first or last or corresponding authorship in the life sciences is required. Should an applicant fail to meet one or more of the above criteria, the applicant must include an explanation with the application. In cases of doubt, the decision-making bodies of the FWF shall decide whether the research qualifications are adequate |

|  |  |
| --- | --- |
| **Country** | Belgium |
| **Funding organisation** | Fund for Scientific Research-FNRS |
| **National contact person** | Dr. Florence Quistinternational@frs-fnrs.be+32 2 504 9351 |
| **Funding commitment**  | 300.000 € |
| **Anticipated number of fundable proposals**  | 1 |
| **Maximum/ Minimum funding per grant awarded to a project partner** | 300.000 € per project for 3 years |
| **Eligibility of partners**  | All eligibility rules and criteria can be found in the [PINT-MULTI regulations](http://www.fnrs.be/docs/Reglement-et-documents/International/FRS-FNRS_PINT-Multi.pdf%22%20%5Ct%20%22_blank). |
| **Eligibility of costs, types and their caps** | All eligibility rules and criteria can be found in the [PINT-MULTI regulations](http://www.fnrs.be/docs/Reglement-et-documents/International/FRS-FNRS_PINT-Multi.pdf%22%20%5Ct%20%22_blank).Please note that personnel costs (Article III.6) have an annual average cap of 80,000 euros for this call.**Clinical studies are not eligible for funding by the F.R.S.-FNRS****“Overhead” is not an eligible cost**. If the project is selected for funding, these costs will be subject to a separate agreement between the institution of the beneficiary and the F.R.S.-FNRS. |
| **Submission of the proposal at the national level** | Applicants to F.R.S.-FNRS funding must provide basic administrative data by submitting an administrative application on [e-space](https://e-space.frs-fnrs.be/) within 5 working days after the general deadline of the ERA4Health JTC2 call to be eligible. Please select the “PINT-MULTI” funding instrument when creating the administrative application. Proposals invited to the second stage will be able to complete the pre-proposal form and provide information for the full proposal upon validation by the F.R.S.-FNRS. |
| **Submission of other information at the national level** | As described in the [PINT-MULTI regulations](http://www.fnrs.be/docs/Reglement-et-documents/International/FRS-FNRS_PINT-Multi.pdf%22%20%5Ct%20%22_blank). |
| **Submission of financial and scientific reports at the national level** | As described in the [PINT-MULTI regulations](http://www.fnrs.be/docs/Reglement-et-documents/International/FRS-FNRS_PINT-Multi.pdf%22%20%5Ct%20%22_blank). |
| **Further guidance** | <https://www.frs-fnrs.be/fr/calendrier-des-appels> |

|  |  |
| --- | --- |
| **Country** | Belgium |
| **Funding organisation** | The Research Foundation – Flanders (FWO) |
| **National contact person** | Toon Monbaliu (FO) Kristien Peeters (SBO)europe@fwo.be europe@fwo.be+32 (0)2 550 15 70 +32 (0)2 550 15 95 |
| **Funding commitment**  | 700.000 EUR |
| **Anticipated number of fundable proposals**  | 2-3 |
| **Maximum/ Minimum funding per grant awarded to a project partner** | Maximum 350.000 EUR per project/consortium (overhead included). |
| **Eligibility of partners**  | The FWO integrates two of its funding channels within this multilateral framework. The choice of funding channel depends on the type of project the researchers from Flanders wish to undertake.The eligibility of research institutions and its researchers can be verified in the relevant and respective chosen funding channels regulations, which can be consulted on the FWO website:* [FWO Research Projects (FO)](https://www.fwo.be/en/fellowships-funding/research-projects/junior-and-senior-research-projects/regulations-projects-2019/)
* [Strategic Basic Research (SBO)](https://www.fwo.be/en/fellowships-funding/research-projects/sbo-projects/regulations-strategic-basic-research-sbo/)
 |
| **Eligibility of costs, types and their caps** | The respective funding channel regulations apply (see links to national rules above), and both are capped at max. 350.000 EUR per project/consortium (incl. overhead, for which the calculation method diverges per funding channel).The FWO foresees a budget of 700.000 EUR, which allows for the funding of at least 2 projects.For the overhead calculation, the fundamental (FO) and strategic research projects (SBO) entail the same approach: a structural overhead rate should be applied on the total project costs, with an overhead rate of 6% for ‘FO’ projects, and a 17% overhead rate for ‘SBO’ projects. Some practical examples:* FO: the sum of all costs (personnel, consumables, travel, subcontracting, etc.) amounts to 200.000 EUR, then the overhead will amount to 12.000 EUR (6% of 200.000 EUR) and the total requested cost is 212.000 EUR. This total requested cost may never exceed the max. available amount of 350.000 EUR.
* SBO: the sum of all costs (personnel, consumables, travel, subcontracting, etc.) amounts to 200.000 EUR, then the overhead will amount to 34.000 EUR (17% of 200.000 EUR) and the total requested cost is 234.000 EUR. This total requested cost may never exceed the max. available amount of 350.000 EUR.

**The FWO funds up to pre-clinical research.** |
| **Submission of the proposal at the national level** | No national project submission is required.However, **when the FWO SBO project route is chosen, the researchers are asked to provide proactively, and before the pre-proposal submission deadline (preferably one week in advance), a concise – but to the point – valorisation plan to the FWO** (no fixed format, max. two A4-pages), which:1. clarifies the economic and/or societal valorisation context within, and added value for Flanders (and also internationally preferably);
2. mentions the involved – and specific - actors from Flanders.

This document can be sent towards the europe@fwo.be email address.**Failure to comply with this requirement can lead to ineligibility.** |
| **Submission of financial and scientific reports at the national level** | * No additional, national scientific reporting is required: the ERA4Health ‘Cardinnov’ call reporting requirements suffice in this regard.
* Financial reporting is similar to the national framework. One additional feature: at the end of the project the FWO will ask for a cost statement, in the light of its own reporting requirements.
 |
| **Additional eligibility rulesFurther guidance** | * Participation in this call does not interfere with the ‘regular/national’ project submission framework, and is consequently not taken into account for calculating the max. available number of new applications and running projects combined. However, **researchers can only participate within 2 different international consortia in this call** (and only once if they act as coordinator in one of the proposals).
* Projects aiming at the development of a spin-off company are not eligible in this context.
* The **project duration is limited to 36 months**, which implies the funding has to be budgeted and spent accordingly. An automatic prolongation and using positive (financial) balances after the end date is not applicable in this framework. As such article 28 of the [FWO Research Projects](https://www.fwo.be/en/fellowships-funding/research-projects/junior-and-senior-research-projects/regulations-projects-2019/) and article 14 of the [Strategic Basic Research (SBO)](https://www.fwo.be/en/fellowships-funding/research-projects/sbo-projects/regulations-strategic-basic-research-sbo/) regulations do not apply in this context.
* The PI, for each of the participating institutions applying for FWO funds, must hold an **appointment that fully covers the duration of the research project.** Linked to this, and when it comes to the [FWO research project regulations (FO)](https://www.fwo.be/en/fellowships-funding/research-projects/junior-and-senior-research-projects/regulations-projects-2019/): article 10, §7 is not applicable in this framework. I.e. supervisors (-spokespersons), or coordinators/consortium partners who are granted **emeritus** status during the calendar year of submission of the project application or during the duration of the project are **not eligible**.
* It is strongly advised to contact the FWO contact persons mentioned above, in order not to jeopardize any research projects/consortia.
 |

|  |  |
| --- | --- |
| **Country** | France |
| **Funding organisation** | French Research Funding Agency |
| **National contact person** | Dr. Séverine OlivierPhone number: +33 1 73 54 81 74Dr. Martine BatouxPhone number: +33 1 73 54 81 40Era4healthcall@agencerecherche.fr |
| **Funding commitment**  | 2 500 000 € |
| **Anticipated number of fundable proposals**  | 7-10 |
| **Maximum/ Minimum funding per grant awarded to a project partner** | ANR funding will be limited to 250 000 € per French applicant. For a French Partner taking over the coordination of the project, the maximum budget can be increased up to 300 000 €.Minimum amount per partner: 15 000 €.Maximum amount per project: 400 000 €.  |
| **Eligibility of partners**  | ANR may finance fundamental research, industrial research and experimental developments. Funded Partners must have their primary establishment in France and/or in the EU with a secondary establishment in France. Within this framework, research institutions such as EPST, EPIC, Universities, Hospitals as well as most Foundations, Associations and Enterprises can apply. Entities leading research are entitled to apply (eg: EPST, EPIC, Universities, Hospitals as well as most Foundations, Associations and Enterprises…). This list is not comprehensive and funding rates vary. Please fill the [form related to economical activities](https://anr.fr/fileadmin/documents/2022/DECLARATION-ON-THE-ECONOMIC-ACTIVITIES-OF-AN-ANR-PROJECT-PARTNER.pdf) to identify your funding rate and consult the ANR Funding regulations for more details:<http://www.agence-nationale-recherche.fr/RF> Please note that companies [with economic difficulties](https://anr.fr/fileadmin/documents/2021/Simulation-financement-ANR-EED-2021.xls) are excluded from ANR subventions.Countries subject to sanctions applicable to the research field by the European Union authorities are excluded from this call. Projects involving Partners established in these countries will be declared ineligible by the ANR. At the date of publication, these exclusions concern partners from the following countries Russia, Belarus. This list may evolve in case of new sanctions decided by the European Union. |
| **Eligibility of costs, types and their caps** | Standard ANR funding rules apply for eligible costs, unless stated otherwise in the Annex « *Modalités pour les partenaires sollicitant une aide de l’ANR* ». These rules are specified in ANR’s “ANR Funding regulations” along with the an explanatory note available at: <https://anr.fr/fileadmin/documents/2017/ANR-RF-Fiche-COUTS.pdf> Eligible costs (e.g.: personnel costs, costs of instruments and equipment, additional overheads and other operating expenses incurred directly as a result of the research project such as, for instance: travel costs) and funding rates vary based on the type of research and research partner. Please note that expenses related to permanent staff stipends are not eligible for the Beneficiaries “à coût marginal”. |
| **Submission of the proposal at the national level** | No additional documents should be submitted to ANR during the submission phase. |
| **Submission of other information at the national level** | When a project is selected for funding, administrative and financial data of the partners funded by ANR must be entered by the applicant on the ANR platform. |
| **Submission of financial and scientific reports at the national level** | The ANR funded partners must communicate to ANR the required Scientific reports, Consortium Agreement, Data management plans according to the funding contract and as required to the project coordinator by ERA4Health. Financial reports must be communicated to ANR according to the provisions of ANR Funding regulations. If applicable, Declarations of Due Diligence for the financed projects (Nagoya Protocol) must also be transmitted to ANR in due time.  |
| **Further guidance** | ANR does not allow double application nor double funding and will not finance projects or part of projects that have been funded through other calls. See Annex « *Modalités pour les partenaires sollicitant une aide de l’ANR* » for additional ANR rules at [https://anr.fr/fileadmin/ aap-ERA4Health-CVD-2023-annexe-fr.pdf](https://anr.fr/fileadmin/%20aap-ERA4Health-CVD-2023-annexe-fr.pdf)The above-mentioned terms and conditions are only summarized translations of those entailed in the ANR Funding regulations and in the Annex. In case of inconsistencies, the terms of the ANR Funding regulations and the Annex shall prevail. Please consult these documents for more details. |

|  |  |
| --- | --- |
| **Country** | Israel |
| **Funding organisation** | Ministry of Health |
| **National contact person** | Dr. Irit Allon Phone: +972 (0)2 5082167 ; Email: irit.allon@moh.health.gov.il Chief Scientist Office, Ministry of Health Orly Spivak Phone: +972 (0) 526314326; Email: orly.spivak@moh.gov.il ; orlee.f@gmail.com Chief Scientist Office, Ministry of Health |
| **Funding commitment**  | 320,000 € |
| **Anticipated number of fundable proposals**  | Up to 2 projects |
| **Maximum/ Minimum funding per grant awarded to a project partner** | Up to 140,000 € Additional 40,000 € for coordination |
| **Eligibility of partners**  | Position in a university, research center or hospital. Research authority must approve position prior to submission. |
| **Eligibility of costs, types and their caps** | Materials and consumables; Travel and hosting (up to 10%); No salaries for applicants; No heavy equipment, Institutional overhead 10%. |
| **Submission of the proposal at the national level** | Prior to submission, researchers will submit to CSO-MOH an abstract approved by their research authority including budget distribution. No submission of abstract can result in declaration of the consortium as ineligible. |
| **Submission of other information at the national level** | If the application involves human or animal experiments, bioethics approvals must be submitted with the application or up to 4 months later. |
| **Submission of financial and scientific reports at the national level** | Required annually. |
| **Further guidance** | Please see detailed instructions of application at the national level and reporting at <http://www.health.gov.il/research-fund>  |

|  |  |
| --- | --- |
| **Country** | Italy |
| **Funding organisation** | Italian Ministry of Health (IT-MoH) [www.salute.gov.it](http://www.salute.gov.it)  |
| **National contact person** | * Gaetano Guglielmi – Head Office 3 – Health Research g.guglielmi@sanita.it
* Anna Ceccarelli – NCP and Programme Officer a.ceccarelli-esterno@sanita.it
* Chiara Ciccarelli – NCP and Programme Officer c.ciccarelli@sanita.it
 |
| **Funding commitment**  | 1,5 M € |
| **Anticipated number of fundable proposals**  | 3 |
| **Maximum/ Minimum funding per grant awarded to a project partner** | Max. 400K € per project  |
| **Eligibility of partners**  | Only IRCCS (Istituti di Ricovero e Cura a Carattere Scientifico) researchers are eligible to apply.**Not fundable:** Universities, other research Institutes, companies.No more than two Italian PIs (Principal Investigators) are eligible to apply for the same project. Simultaneous PI participation in different 2023 JTCs funded by the Ministry of Health is not allowed. |
| **Eligibility of costs, types and their caps** | Direct Costs: * Personnel (only temporary contracts, max 50%);
* Consumables;
* Animals;
* Equipment (only on hire);
* Travel (max 10%);
* Documentation (Max 1%)

Indirect Costs: * Overhead (max 10%, included in the total);

Other indirect costs are not eligible. Transfer of eligible funds abroad is not allowed. Subcontracts are allowed only upon approval, by presenting via Workflow – code ER, a request together with the National pre-elegibility form, the latest 20 days before the deadline of the pre-proposal submission. Italian PAOs can be funded as a sub-contractor of an IRCCS if they fulfil the eligibility criteria of the EC. The maximum cost eligible for a sub-contract is 25.000 Euros (from the IRCCS Budget).Italian PAOs can still participate in Consortia as “Collaborators” with their own funds. |
| **Submission of the proposal at the national level** | In order to expedite the eligibility check process, the Ministry of Health will grant an eligibility clearance to the applicant prior to the submission of the proposals. To this end, **it is mandatory that the applicants fill out and return to the IT-MoH a pre-submission eligibility check form through their IRCCS, using WFR System-> ER communication** **code,** before submitting their proposal to the Joint Call Secretariat.It is strongly recommended that the form, completed and duly signed, is returned **at least 10 working days before the proposal submission deadline.** Applicants will be sent written notification of their eligibility status. Changes in acronyms and budgets provided in the pre-submission eligibility check are not allowed.The pre-eligibility form can be downloaded here: http://www.salute.gov.it/imgs/C\_17\_pagineAree\_4441\_listaFile\_itemName\_0\_file.pdf |
| **Submission of other information at the national level** | - |
| **Submission of financial and scientific reports at the national level** | Submission of annual scientific and financial reports at the national level will be required according to the rules of the Ministry of Health (Ricerca Corrente).  |
| **Further guidance** | Further information on the rules of the Ministry of Health can be requested to the national contact persons. |

|  |  |
| --- | --- |
| **Country** | Italy  |
| **Funding organisation** | Ministero dell’Università e della Ricerca  |
| **National contact person** | Aldo Covello Aldo.covello@mur.gov.itMaria Bianco Maria.bianco@mur.gov.it |
| **Funding commitment**  | **Euro 1.000.000** out of which an amount of EUR 400,000 will be allocated on projects with a young researcher (younger than 40 years) as Principal Investigator for the Italian partners.  |
| **Anticipated number of fundable proposals**  | 5 |
| **Maximum funding per grant awarded to a project partner** | **200.000 Euro** |
| **Eligibility of partners**  | The following entities are eligible, providing that they have stable organization in Italy: enterprises including foundations and non-economic entities, universities, research institutions, research organizations in accordance with EU Reg. n. 651/2014 of the European Commission - June 17, 2014, patient advocacy organizations, local and regional administrations; Any participant, in order to be eligible, must comply with the eligibility criteria listed in the “Avviso integrativo nazionale”. |
| **Eligibility of costs, types and their caps** | All costs incurred during the lifetime of the project under the following categories are eligible: Personnel, Equipment, Consulting and equivalent services, Consumables and Overheads. Overheads (“Spese generali”) shall be calculated as a percentage of the personnel costs and cannot be higher than 50% of them. Travel expenses, dissemination and coordination costs are to be included in the overheads.All activities classifiable as Basic research, Industrial research and Experimental development are eligible for funding. Furthermore, Basic Research and Industrial research activities must be predominant with respect to Experimental development activities (in terms of costs).The amount of funding which can be granted to each beneficiary is calculated multiplying the eligible costs for the funding rates lister hereafter:Basic research: 70%Industrial Research: 50%Experimental Development: 25% |
| **Submission of the proposal at the national level** |  |
| **Submission of other information at the national level** | In addition to the project proposal, which shall be submitted at European level, the Italian participants are requested to submit a national additional application to MUR, through the national web platform, available at the following link: <https://banditransnazionali-miur.cineca.it> **This national additional application must be submitted by the same deadline established in the international joint call for pre-proposal submission. Any participant who does not submit its national documents by the deadline will be considered not eligible for funding.** More information on the national documentation to be submitted to MUR is available at the web page dedicated to the partnership ERA4Health: <http://www.ricercainternazionale.miur.it/era/european-partnership-2021-27/era4health.aspx>It is strongly recommended to contact the National Contact Persons already in early stage of project preparation.The admission for funding is subject to the adoption of the necessary accounting and administrative measures for the allocation of the resources. Funded participants will be requested to submit financial and scientific reports to MUR. The criteria and provisions provided herewith are intended only for informative purposes. The complete list of criteria and provisions legally valid, which must be respected by all the Italian participants, is included in the “Avviso integrativo nazionale”, which will be published on the MUR website, and in the applicable Italian laws.**Applicable laws and rules:*** Decreto legge n. 83/2012
* Decreto Ministeriale n. 1314 del 14 dicembre 2021
* Decreto Ministeriale n. 1368 del 24 dicembre 2021

Avviso integrativo nazionale |
| **Submission of financial and scientific reports at the national level** |  |
| **Further guidance** | **National website:** <http://www.ricercainternazionale.miur.it/era/european-partnership-2021-27/era4health.aspx>**National submission platform:** <https://banditransnazionali-miur.cineca.it>**Relevant Document:*** Decreto legge n. 83/2012
* Decreto Ministeriale n. 1314 del 14 dicembre 2021
* Decreto Ministeriale n. 1368 del 24 dicembre 2021
* Avviso integrativo nazionale
 |

|  |  |
| --- | --- |
| **Country** | Latvia |
| **Funding organisation** | Latvian Council of Science |
| **National contact person** | Maija Bundule E‐mail: Maija.Bundule@lzp.gov.lv Tel: +371- 26514481 Uldis BerkisE-mail: Uldis.Berkis@lzp.gov.lvTel.: +371-29472349 |
| **Funding commitment**  | 0,5M EUR  |
| **Anticipated number of fundable proposals**  | 2 |
| **Maximum/ Minimum funding per grant awarded to a project partner** | 300.000 Euros per partner, not exceeding 100.000 EUR per yearFunding rates under R651/2014 shall be respected |
| **Eligibility of partners**  | 1) Research institutions registered in the Latvian Registry of Scientific Institutions, e.g. - Research Institutes - Universities And must have the status of Research and knowledge dissemination organization (Regulation EC 651/2014)  2) Business enterprises entered into the Latvian Commercial registry as companies, assumed they are eligible to do the specific research and have specific capacity and resources to do the research in Latvia and have their main activity in Latvia. Limitations of EU legislation apply (R651/2014) together with financial reporting requirements, in this case this is state aid. Two previous statements with sworn auditor’s approval should be provided and they must reflect the correspondence to the regulation as well as evidence of previous scientific activity and presence of capacity. |
| **Eligibility of costs, types and their caps** | * Personnel costs incl. taxes;
* Consumables;
* Subcontracts (up to 25% of direct costs), needs detailed justification, includes all external services, project core activities cannot be subcontracted;
* Equipment (only depreciation costs during project directly attributable to project tasks);
* Replaceable and fully consumable during project elements of equipment (e.g. electrodes);
* Travels (according to travel plan);

Indirect costs (up to 25% of direct costs excluding subcontracting). |
| **Submission of the proposal at the national level** | No |
| **Submission of other information at the national level** | To receive funding by LCS, Consortium agreement duly signed should be presented. Enterprises shall provide audited statements of 2 previous closed financial periods on request. Final audit according to the LCS regulations. |
| **Submission of financial and scientific reports at the national level** | Annual or in some cases half-annual financial and scientific reporting is mandatory.  |
| **Further guidance** | Support is provided according to Provisions Nr 259, 26.05.2015 of the Latvian Cabinet of Ministers [(http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba-dalibaistarptautiskas-sadarbibas-programmas-petniecibas-un-tehnologiju-joma)](http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba-dalibai-starptautiskas-sadarbibas-programmas-petniecibas-un-tehnologiju-joma) These provisions should be respected without exceptions. The maximum rates should respect the Provisions. The requirements in the provisions to specific applicant groups must be respected. LCS cannot fund implementation support, nor training activities.LCS is funding only research. |

|  |  |
| --- | --- |
| **Country** | Lithuania |
| **Funding organisation** | Research Council of Lithuania (Lietuvos mokslo taryba), LMT |
| **National contact person** | Živilė RuželėE-mail: zivile.ruzele@lmt.lt; Tel. +37067614383 |
| **Funding commitment**  | 200 000 Eur |
| **Anticipated number of fundable proposals**  | 1 |
| **Maximum/ Minimum funding per grant awarded to a project partner** | Within a single project proposal, the maximum funding can be up to EUR 100 000 for a consortium partner or up to EUR 150 000 for a coordinator/2 eligible LT partners in the consortium |
| **Eligibility of partners**  | * Lithuanian research and education institutions: Universities, Research centres (which is listed in the Register of Ministry of Education, Science and sports of Republic of Lithuania)
* Public health care institutions: University hospitals, other public hospitals.

Any private or public legal entity can be a partner of the main applicant. |
| **Eligibility of costs, types and their caps** | Direct costs: personnel, travel, purchase (assets, servises, consumables), subcontracting.Overheads (indirect costs): up to 20 % from direct costs. |
| **Submission of the proposal at the national level** | Not required |
| **Submission of other information at the national level** | If proposal is granted Lithuanian partner must submit the detailed budget for the project implementation prior to the grant agreement signature. |
| **Submission of financial and scientific reports at the national level** | Quarterly and yearly financial reports and two (2) scientific reports (mid-term and final) are required. |
| **Further guidance** | Please contact National contact person |

|  |  |
| --- | --- |
| **Country** | The Netherlands |
| **Funding organisation** | NWOThe funds for this call are provided by NWO and the Dutch Heart Foundation. |
| **National contact person** | The call is coordinated by ZonMw on behalf of NWO.Dr. Rob Diemel, ERA4Health@zonmw.nl, +31 70 349 5252 |
| **Funding commitment**  | € 2.700.000 in total (€ 2.000.000 from NWO and € 700.000 from the Dutch Heart Foundation) |
| **Anticipated number of fundable proposals**  | 9 |
| **Maximum funding per grant awarded to a project partner** | € 300.000 (= total amount for all Dutch partners per consortium) |
| **Eligibility of partners**  | In this National Annex an Applicant is defined as a researcher from the Netherlands applying for funding (i.e. the Dutch part of a European consortium).Full, associate and assistant professors, and other researchers with a comparable position\* may submit an application (i.e. participate in a consortium and request funding) if they have a tenured position (and therefore a paid position for an indefinite period) or a tenure track agreement at one of the following research organisations: * Universities located in the Kingdom of the Netherlands;
* University medical centres;
* Institutes affiliated to the Royal Netherlands Academy of Arts and Sciences (KNAW) or NWO;
* The Netherlands Cancer Institute;
* The Max Planck Institute for Psycholinguistics in Nijmegen;
* Naturalis Biodiversity Center;
* Advanced Research Centre for NanoLithography (ARCNL);
* Princess Máxima Center.

*\*A comparable position refers to a researcher that has a demonstrable and comparable number of years of experience in carrying out scientific research and supervising other researchers as a full, associate or assistant professor.* Persons with a zero-hour employment agreement or with a contract for a limited period of time (other than a tenure track appointment) may not submit a proposal. It could be the case that the applicant’s tenure track agreement ends before the intended completion date of the project for which funding is applied for, or that before that date, the applicant’s tenured contract ends due to the applicant reaching retirement age. In that case, the applicant needs to include a statement from their employer in which the organisation concerned guarantees that the project and all project members for whom funding has been requested will receive adequate supervision for the full duration of the project. Please, submit this statement with both the outline and full proposal by email to ERA4Health@zonmw.nl .Applicants with a part-time contract should guarantee adequate supervision of the project and all project members for whom funding is requested.An application for funding (i.e. the Dutch part of a European consortium) has a single main applicant (i.e. Dutch Partner or Coordinator in the European consortium), responsible for scientific and financial management. * An applicant may only request NWO funding for one project (part of a European consortium) in this call.
* Applicants may not apply for a scientific position for themselves.
 |
| **Eligibility of costs, types and their caps** | The NWO budget modules (including the maximum amount) available for this call for proposals are listed below. Apply only for funding that is vital to realise the project. ***Available budget modules*** * *Postdoc* – at least 12 full months and at most 36 full-time months, according to UNL or NFU rates
* *Research leave* – max. 5 months, 1 FTE, according to UNL or NFU rates
* *Material costs* – max. € 15.000 per year per full-time scientific position (postdoc)
* *Knowledge utilisation* - max. € 25.000
* *Internationalisation* - max. € 25.000

For the budget module “Postdoc”, a one-off individual bench fee of € 5.000 is added on top of the salary costs to encourage the scientific career of the project employee funded by NWO. Note that PhD positions cannot be applied for in this call, due to the maximum project duration of 3 years. Postdoc salary costs and Research leave are funded in accordance with the UNL or NFU salary tables applicable at the moment the grant is awarded ([https://www.nwo.nl/en/funding/funding+process+explained/salary+tables](https://www.nwo.nl/en/funding/funding%2Bprocess%2Bexplained/salary%2Btables)). |
| **Submission of the proposal at the national level** | Once proposals are selected for funding, the Dutch partner(s) in those proposals will be notified. |
| **Submission of other information at the national level** | Applicants are required to submit a mandatory NWO budget form in the full proposal stage separately per email to ERA4Health@zonmw.nl . Please refer to the detailed explanation of NWO budget modules to see which costs are eligible for NWO funding*.* It is recommended to use the NWO financial details form already in the pre-proposal stage to confirm eligibility of budget items. A more detailed explanation of the NWO budget template can befound via the following web page: [www.nwo.nl/era4health](http://www.nwo.nl/era4health) (to go the call and information page, see “open calls”)For each granted project that includes a project partner from the Netherlands, a signed Consortium Agreement including a description of the handling of Intellectual Property Rights should be emailed to ERA4Health@zonmw.nl within 6 months from the start of the project.  |
| **Submission of financial and scientific reports at the national level** | Submission of financial and scientific reports at national level is required in accordance with the rules of NWO. A midterm scientific report will be required for the Dutch partner(s) of the consortium project.  |
| **Further guidance** | **Important:** In this call, Dutch researchers are only allowed to conduct research that falls within the category ‘Innovation applied research projects’ as described in this call text.The Dutch Heart Foundation upholds the policy to not provide funding to applicants whose proposals are influenced by the tobacco industry. Applicants are advised to take this into consideration.The NWO Grant Rules 2017 and the Approval of funding for scientificresearch 2008 are applicable to the part of the project’s budgetcovered by the grant from NWO. Any arrangements made regardingthe part of the project’s budget covered by the grant from NWO, forinstance in a consortium agreement, must comply with the NWO Grant Rules 2017 and the European legislation on state aid. |

|  |  |
| --- | --- |
| **Country** | Poland |
| **Funding organisation** | National Centre for Research and Development |
| **National contact person** | Dr Marcin Chmielewski T: +48 22 39 07 109 M: +48 571 226 666 marcin.chmielewski@ncbr.gov.plMateusz SkutnikT: +48 22 39 07 148 M: +48 515 339 175mateusz.skutnik@ncbr.gov.plDepartment of International Cooperation, ul. Chmielna 69, 00-801 Warszawa, Poland |
| **Funding commitment**  | 1 250 000 € |
| **Anticipated number of fundable proposals**  | 3 |
| **Maximum/ Minimum funding per grant awarded to a project partner** | 400 000 € per project |
| **Eligibility of partners**  | Following entities are eligible to apply:* Micro, Small, Medium and Large enterprise;
* Research organisation;
* Group of entities (within the meaning of art. 37 section 1, point 1a of The Act of 30 April 2010 on the National Centre for Research and Development, published in Journal of Laws item 2279, 2022;).

 Entity must be registered in Poland;* For enterprises it is strongly advised to state in the Pre-proposal application form the KRS number of the enterprise and the size of the enterprise (micro/small, medium, large);
* A condition for the participation of a group of entities as the Applicant in the competition is its formal existence on the date of submission of the pre-proposal, confirmed by its members concluding, at least conditionally, agreement on the creation of a group of entities;

Please note that group of entities counts as at least two project partners from Poland (it meets the limit on the number of participants from the same country, please refer to call text for details). |
| **Eligibility of costs, types and their caps** | The eligible costs shall be the following:1. **personnel costs** (researchers, technicians and other supporting staff to the extent employed on the research project);2. **operating costs** including costs of instruments, equipment, technical knowledge, patents, costs for buildings and land, costs of materials, supplies and similar products incurred directly as a result of the research activity.3. **cost of contractual research**, costs of consultancy and equivalent services used exclusively for the research activity; this cost type cannot account for more than 70% of all eligible costs of a project; the subcontracting can be obtained from consortium partner only in justified case, this need will be verified by a national expert panel.4. **additional overheads** incurred indirectly as a result of the research project; that costs are exactly 25% of eligible project costs and are counted as a multiplication by percentage given above and the rest of direct costs, excluding subcontracting (3); It means 4 = (1+2)\*25%.Funding quota of Polish participants can be up to 100% for research organisations. In the case of enterprises, funding quota will be decided on a case-by-case basis depending on the size of the company, type of research/development, risk associated with the research activities and commercial perspective of exploitation, under the Regulation of the Minister of Science and Higher Education of 19 August 2020 on criteria and rules on granting state aid by the National Centre for Research and Development, published in Journal of Laws item 1456, 2020.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Large Enterprises** | **Medium Enterprises** | **Small Enterprises** | **Research organizations** |
| **Fundamental/Basic Research** | Not eligible | Not eligible | Not eligible | Not eligible |
| **Industrial/Applied Research** | Up to 50+15 (max 65 %) | Up to 50+10+15(max 75 %) | Up to 50+20+15 (max 80 %) | Up to100 % |
| **Experimental development** | Up to 25+15 (max 40 %) | Up to 25+10+15 (max 50 %) | Up to 25+20+15 (max 60 %) | Up to100 % |

Only Industrial/Applied Research and Experimental Development will be funded. Other type of activities (e.g. coordination, dissemination, management) is not eligible for funding as separate research tasks in the project schedule. |
| **Submission of the proposal at the national level** | Polish Participants will be informed and invited to submit Polish proposal once the international evaluation and the ranking list will be established. |
| **Submission of other information at the national level** | - |
| **Submission of financial and scientific reports at the national level** | Annual scientific reports are obligatory. |
| **Further guidance** | Sample documents are available at:<https://www.gov.pl/web/ncbr/wniosek-krajowy>We encourage you to learn about and use our "PartFinder" (Partner Search Tool), which allows you to match science and industry entities from around the World with each other. The search engine is available at: <https://partfinder.ncbr.gov.pl/> |

|  |  |
| --- | --- |
| Country | Portugal |
| Funding organisation | Fundação para a Ciência e a Tecnologia |
| National contact person | Andréia FeijãoRita Cavaleiroera4health@fct.pt |
| Funding commitment  | 250.000 € |
| Anticipated number of fundable proposals  | 1-2 |
| Maximum/ Minimum funding per grant awarded to a project partner | Maximum 250k€ for PT coordination and maximum 150k€ for PT participation. Note: if more than one Portuguese institution participates in each consortium, the budget must be shared. |
| Eligibility of partners  | To be elegible the organisations must be registered in Portugal. Elegible partners as beneficiary institutions are:Higher education institutions, their institutes and R&D Units; State or international laboratories with head office in Portugal; Non-profit private institutions whose main objective is to carry out R&D activities; Other public and private non-profit institutions developing or participating in scientific research activities.Companies of any type and under any legal form if included in SR&TD projects led by non-entrepreneurial entities from the R&I system. |
| Eligibility of costs, types and their caps | Equipment, consumables, human resources, travel, overheads. |
| Submission of the proposal at the national level | Yes, but only for full proposals selected for funding. |
| Submission of other information at the national level | Within 10 working days after the deadline for submitting the pre-proposal, Portuguese teams must send to the National Contact Point from FCT a statement of commitment duly signed by the Researcher in Charge and by the Head of the Portuguese applicant organization, dated and stamped. |
| Submission of financial and scientific reports at the national level | For purposes of follow-up and final assessment, beneficiaries submit annual scientific progress report(s) and one final scientific report through the FCT, I.P. portal and preferentially in English. |
| Further guidance | The information provided above is a summary only. Portuguese institutions must follow FCT’s Legislation, Regulations and Norms. Therefore, it’s necessary the consultation of the detailed and complete information in the “Regulation on Projects Funded Solely by National Funds” at:https://www.fct.pt/apoios/projectos/regulamentofundosnacionais.phtml.enThe dedication (FTE) in transnational projects is not considered for the 100% (FTE) dedication to national projects. |

|  |  |
| --- | --- |
| **Country** | Romania |
| **Funding organisation** | Executive Agency for Higher Education, Research, Development and Innovation Funding |
| **National contact person** | Mihaela Manole E‐mail: mihaela.manole@uefiscdi.roPhone: +40 21 302 38 63 Nicoleta Dumitrache E‐mail: nicoleta.dumitrache@uefiscdi.roPhone: +40 21 302 38 86 |
| **Funding commitment**  | 1,000,000 euro |
| **Anticipated number of fundable proposals**  | 4-5 |
| **Maximum/ Minimum funding per grant awarded to a project partner** | Funding rates vary in accordance with state aid legislation. For more information : https://uefiscdi.ro/pachet-de-informatii-suprogramul-3-2-orizont-2020 250.000 euro for all romanian partners in case a Romanian institution is the Coordinator;  200.000 for all romanian partners in case a Romanian institution is not the Coordinator. |
| **Eligibility of partners**  | Eligible entities for funding are universities, public institutions, R&D national institutions, joint-stock companies, SME’s and Large companies, NGOs (associations, foundations, etc.), others. |
| **Eligibility of costs, types and their caps** | a. Staff costs; b. Logistics expenses - Capital expenditure; - Expenditure on stocks - supplies and inventory items; - Expenditure on services performed by third parties cannot exceed 25 % of the funding from the public budget. The subcontracted parts should not be core/substantial parts of the project work; c. Travel expenses; d. Overhead (indirect costs) is calculated as a percentage of direct costs: staff costs, logistics costs (excluding capital costs and cost for subcontracting) and travel expenses. Indirect costs will not exceed 20 % of direct costs. |
| **Submission of the proposal at the national level** | NO |
| **Submission of other information at the national level** | NO |
| **Submission of financial and scientific reports at the national level** | NO |
| **Further guidance** | Maximum funding percentages:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Type of research** | **Large Enterprises** | **Medium Enterprises** | **Small Enterprises** | **Universities and research organisations** |
| **Fundamental/Basic Research** | 100 | 100 | 100 | 100 |
| **Industrial/Applied Research** | Up to 50+15 (max 65) | Up to 60+15 (max 75%) | Up to 70+10 (max 85) | 100 |
| **Experimental development** | Up to 25+15 (max 40) | Up to 35+15 (max 50) | Up to 40+15 (max 65) | 100 |

 |

|  |  |
| --- | --- |
| **Country** | Slovakia |
| **Funding organisation** | Slovak Academy of Sciences |
| **National contact person** | Katarina Bibovabibova@up.upsav.sk  |
| **Funding commitment**  | 240.000€ |
| **Anticipated number of fundable proposals**  | 2 |
| **Maximum/ Minimum funding per grant awarded to a project partner** | Up to 120.000€ per project |
| **Eligibility of partners**  | Only research Institutes of the Slovak Academy of Sciences are eligible organisations for funding by SAS (up to 100%).1. The Slovak principal investigator must have a job contract for more than 50% working hours in the SAS organization for which the project proposal or participation in the project proposal is submitted.2. Other researchers, except for doctoral students, must have a working relationship with the SAS organization.3. Each researcher of the Slovak partner research team of a project consortium (other than the Slovak Principal Investigator) must have a job contract with or a fellowship with the Slovak Principal Investigator, lasting until the end of the project or beyond. |
| **Eligibility of costs, types and their caps** | Total eligible costs = Permanent salaries + Other costs (DC + IC)• Permanent salaries 45 000 € (36 months)• Other costs: 75 000 € (36 months)Direct costs (DC): Personnel (max. 15% of DC), Consumables, Equipment (max. 40% of DC) and Travel costs Indirect costs (IC, Overheads): max. 20 % of DC. Limitations and specifications are available: ([Financial rules for awarding SAS grants for international research projects](https://www.sav.sk/index.php?lang=sk&doc=services-news&source_no=25&news_no=7569))  |
| **Submission of the proposal at the national level** | Submission of the proposal at the national level will be required once the international evaluation has taken place and the ranking list has been endorsed by the Joint Call Steering Committee (CSC). The Slovak partner will be informed about recommendation for funding by the project consortium coordinator and invited by SAS **to submit the national proposal form (MVTS form)**. The Presidium of SAS makes the final decision concerning the approval of funding (according to internal rules of SAS). |
| **Submission of other information at the national level** | - |
| **Submission of financial and scientific reports at the national level** | Annual financial report within 1 month after the end of each calendar year during the duration of the funded project |
| **Further guidance** |  |

|  |  |
| --- | --- |
| **Country** | Spain |
| **Funding organisation** | Agencia Estatal de Investigación |
| **National contact person** | María GaviraEra4Health@aei.gob.es |
| **Funding commitment**  | 1.000.000 € |
| **Anticipated number of fundable proposals**  | 5-6 |
| **Maximum/ Minimum funding per grant awarded to a project partner** | A maximum of two Spanish Partners requesting funding in the same Proposal are allowed (including those partners funded by the ISCIII). The following funding limits (including direct + 21 % of indirect costs) are considered eligibility criteria. Proposals not respecting these limits could be declared ineligible. Please, indicate separately direct and indirect cost and keep amounts multiple of 1000. In any case, the AEI will round the numbers to a multiple of 1000.* If a Spanish Partner requesting funding to the AEI is NOT the Coordinator of the transnational project:
* € 200.000, if there is only one Spanish Partner requesting funding to the AEI in the proposal.
* € 250.000, if there are two Spanish Partners requesting funding to the AEI in the proposal.
* If a Spanish Partner requesting funding to the AEI IS the Coordinator of the transnational project:
* € 300.000, if there is only one Spanish Partner in the proposal, acting as a coordinator.
* € 350.000, if there is one Spanish Partner in addition to the Spanish Coordinator in the proposal, both requesting funding to the AEI.

Centres formed by different Spanish legal entities will be considered as a unique entity, and thus the maximum funding should not exceed the limits per proposal established above (for example mixed centres).  |
| **Eligibility of partners**  | **Eligibility for organizations (please read carefully)**Non-profit research organizations (such as universities, public research institutions, technological centres and other private non-profit institutions performing RDI activities in Spain), as the general requirements established for [PCI 2022-](https://www.aei.gob.es/convocatorias/buscador-convocatorias/proyectos-colaboracion-internacional-pci2022-2)2 call. They must have been previously beneficiaries of any of the AEI calls. They have to ensure contractual relationship with the Principal Investigator during all the time of development of the project.**Eligibility criteria for PIs**The Spanish Principal Investigators (PIs) must hold a PhD degree.PIs must be eligible according to the requirements of [PCI 2022-](https://www.aei.gob.es/convocatorias/buscador-convocatorias/proyectos-colaboracion-internacional-pci2022-2)2 call and must have experience as investigators (not necessarily as PIs) in projects funded by the different *Planes Estatales I+D+i* from 2013 onwards, ERC Grants, European Framework Programmes or other relevant national or international programmes.**Incompatibilities (these must be taken into account when participating in different ERA-Nets or other international initiatives):*** PIs will not be eligible for funding if they apply as PIs to more than one proposal in this transnational joint call (including those requesting to the ISCIII), to more than one proposal in the same Spanish PCI call and/or to PCI calls of consecutive years.
* If the same PI submits two or more proposals to the present call, all but one will be declared ineligible, without the possibility of changing the PI.
* A PI that has been granted a PCI the previous year will be declared ineligible, without the possibility of changing the PI.
* PIs must remain unchanged between the proposal of this transnational joint call and the national PCI call.

The AEI will avoid double funding and will not grant projects or parts of projects already funded through other national or EU calls. |
| **Eligibility of costs, types and their caps** | * Members of the research team will not be considered eligible costs.
* Direct costs such as current costs, small scientific equipment, disposable materials, travelling expenses, coordination costs, and other costs that can be justified as necessary to carry out the proposed activities. VAT may not be eligible, depending on the application of RRF funds.
* Overheads are eligible (21% of the direct costs, including outsourcing).
* Subcontracting should not exceed 25% of total final budget (excluding overheads).
* Clinical trials are eligible up to phase 1, with a maximum of 50% of the total budget
 |
| **Submission of the proposal at the national level** | **Submission of the pre and full proposal at the national level:** Not mandatory. However, PIs and beneficiaries are strongly encouraged to check eligibility before submitting a pre proposal, since **no changes will be accepted afterwords**. No Pi or beneficiary changes will be accepted between pre and full proposal and the national call. **National level proposal. Funding Programme:** The framework for this funding action is the Plan Estatal de Investigación Científica, Técnica e Innovación 2021‐2023. On a national level, the Call will be managed by the Subdivisión de Programas Científico‐Técnicos Transversales, Fortalecimiento y Excelencia (STRAN) of the AEI. **Instrument for funding**The instrument for funding the Spanish groups is the call for “Proyectos de Colaboración internacional (PCI)”. Please consult the requirements of [PCI2022-](https://www.aei.gob.es/convocatorias/buscador-convocatorias/proyectos-colaboracion-internacional-pci2022-2)2 as they will be similar. **Data Protection:** By submitting a grant application to the AEI, the applicants consent to communication of the data contained in the application to other public administrations, with the aim of further processing of the data for historical, statistical or scientific purposes, within the framework of the Organic Law 3/2018, of December 5, on Personal Data |
| **Submission of other information at the national level** | Please consult the requirements of [PCI2022-](https://www.aei.gob.es/convocatorias/buscador-convocatorias/proyectos-colaboracion-internacional-pci2022-2)2 as they will be similar. Applicants are encouraged to carefully read the call and the general requirements. |
| **Submission of financial and scientific reports at the national level** | Please consult the requirements of PCI2022-2 as they will be similar. Applicants are encouraged to carefully read the call and the general requirements. |
| **Further guidance** | **Acknowledgement**: Any publication or dissemination activity resulting from the granted projects must acknowledge funding by the Agencia Estatal de Investigación according to AEI’s web [guidelines](https://www.aei.gob.es/ayudas-concedidas/comunicacion-publicidad-ayudas-concedidas).Beneficiaries are obliged by these requirements and those of the internacional call. |

|  |  |
| --- | --- |
| **Country** | Spain |
| **Funding organisation** | Institute of Health Carlos III (Instituto de Salud Carlos III- ISCIII) |
| **National contact person** | **Mauricio García Franco**email: mauriciog@isciii.esTel: (+34) 91 822 28 85 |
| **Funding commitment**  | National Programme: Acción Estratégica en Salud (AES 2023)1.600.000 € (pending of approval of Spanish State Budget) |
| **Anticipated number of fundable proposals**  | 6-9  |
| **Maximum/ Minimum funding per grant awarded to a project partner** | **Maximum funding from ISCIII per awarded Spanish project partner:**• Up to **180,000 €** per partner (overheads included)• Up to **260,000 €** per coordinator (overheads included) Overheads according to AES 2023 : 25% **Projects’ duration**: from 24 months to 36 monthsThe level of funding will take into account the evaluation of the collaborative proposal, the scientific quality of the Spanish group, the added value of the international collaboration, the participation of the primary health care and the financial resources available.  |
| **Eligibility of partners**  | **Eligible Institutions:*** **Accredited Health Research Institutes** (Institutos de Investigación Sanitaria acreditados, IIS). Accredited according to the RD 279/2016 (These institutions may manage research via a foundation regulated according to the Spanish Act 50/ 2002, of December 26th). See the list of IIS in [this link.](https://www.isciii.es/QuienesSomos/IIS/Paginas/Acreditacion.aspx)
* **Hospitals, primary health care or public health administration of the Spanish National Health System** (SNS). These institutions may manage research via a foundation regulated in accordance to the Spanish Act 50/2002, of December 26th (a copy of the foundation’s statutes may be submitted).
* **CIBER**.Team members applying to the call must be from at least two groups belonging to CIBER in two different home institutions and one of these two should be a Hospital, primary health care or public health administration of the Spanish National Health System (SNS) or Accredited Health Research Institutes (Institutos de Investigación Sanitaria acreditados, IIS). Please contact Cristina Rodríguez (cristina.rodriguez@ciberisciii.es) for more information related to CIBER’s eligibility.
* **Applicants from ISCIII** are eligible. Eligibility criteria from AESI 2023 apply.
* **Public Research Centres exclusively working in the field of cardiovascular diseases.**
* **Private health entities and institutions, Public Research Institutions** (OPIs) as defined in article 47 of Law 14/2011, of 1 June, in accordance with the provisions of Royal Decree 202/2021, of 30 March, **public Universities and private Universities with proven R&D activity capacity, other public R&D centres.** These entities can **only** participate if they apply together with hospitals, primary health care or public health administration of the Spanish National Health System (or Accredited Health Research Institutes (IIS) in the same proposal. It is not allowed to apply independently, thus **there must be two beneficiary Spanish institutions requesting funding to ISCIII in the same proposal.**
* Please be careful that in AES2023 some specific Institutions may be declared as ineligible to receive funds by ISCIII in this call.
* Same beneficiary institution cannot participate with more than one partner in the same project proposal.
 |
| **Eligibility of PI and team members** | * Principal Investigators (PI) can only participate in one project proposal per call.

• Principal Investigators (PIs) belonging to an **Accredited Health Research Institutes** (IIS) could apply **only from the IIS.** • The Principal Investigator (PI) and all members of the research group must belong to the eligible institutions in the call. * Only one PI per beneficiary institution may be funded within the same proposal.
* PIs that has an ongoing International Collaboration (PCIN) project of the same initiative and purpose that this call and that the project has an ending date after the 31st December 2023 will not be able to apply for this call. This incompatibility will affect only to the PI. And this incompatibility will not apply in the case that the PI participate as coordinator in the new application or in the ongoing project.

For additional incompatibilities please review AES2023. **Excluded** personnel as Principal Investigator (PI):• Those undergoing a postgraduate training in Health Specialization (MIR, EIR, FIR, QIR, BIR, PIR, RFIR).• Those undergoing research training (e.g. PhD students, or “Río Hortega” contracts).• Those undergoing postdoctoral training (e.g. “Sara Borrell” or “Juan de la Cierva” contracts).• Researchers contracted by a RICORs and platforms funded by ISCIII. |
| **Eligibility of costs, types and their caps** | **• Personnel costs:*** It will be eligible personnel costs for contracts with the needed professional category (superior technician, BSc (grado), MSc (máster), PhD (doctor) for the project development accordingly to the published salary tables in AES2023 / ISCIII’s webpage.
* Contracts for PhD students will be done in the framework of National Subprogramme for Training (scholarships are not eligible).
* Personnel costs will be eligible with a maximum of 36 PM in total for the personnel contracts altogether.
* The hiring of permanent personnel already belonging to the beneficiary entity or members of the research team will not be considered eligible expenses.

• **Other eligible costs** : Current costs, small scientific equipment, disposable materials, travelling expenses, complementary expenses (use of central and general research support services of the beneficiary entity), publication and dissemination of resultsand other costs as included in AES 2023 that can be justified as necessary to carry out the proposed activities. * **Overheads**, according to AES 2023 (25%)
* • **Double funding of the same concept is not allowed.**
 |
| **Submission of the proposal at the national level** | • National applications will be required by ISCIII. Due to administrative and legal regulations, the Institute of Health Carlos III establishes the **31st October 2023** as the national deadline for the decision on fundable project consortia which includes Spanish partners to be funded by ISCIII, which must present their National application in the period stated in AES 2023 (1-15 November 2023, tentative). Any concerned applicant in a proposal for which no final decision has been made by the deadline of 31.10.2023, could be declared not fundable by ISCIII. |
| **Submission of other information at the national level** | As specified by AES 2023. |
| **Submission of financial and scientific reports at the national level** | As specified by ISCIII’s instructions (please check ISCIII’s webpage). |
| **Requirements on data and repositories** | • Researchers funded by ISCIII must make public the human genomic data, as well as relevant data (phenotype and exposition data) generated inside the funded project and will use open access repositories. Researchers must also make public all the necessary information for the interpretation of these genomic data, including lab protocols, data instruments survey tools. Regarding genomic data it is understood: association of complete genomes (GWAS), matrixes of de polymorphism of a single nucleotide (SNP) and sequence of genome, and transcriptomic, metagenomic, epigenomic and gene expression data. The researchers whose projects are funded by ISCIII are recommended to store their scientific data at the "[ELIXIR Core Data Resources](https://elixir-europe.org/platforms/data/core-data-resources)", or if non-European repositories or data bases are to be used they must be certified by ELIXIR or the US National Center for Biotechnology Information (NCBI).• ISCIII may not fund any project that may require a repository and/or a data base without a plan ensuring sustainability and decommissioning after the end of funding. |
| **Requirements for clinical studies** | Spanish groups that participate in a proposal performing a clinical study, **must include** in their team a member from their scientific node of the EU Clinical Trials Network (SCReN or ECRIN-ERIC) or if it does not apply, a member from the personnel of their Clinical Research Supporting Platform of their institutions (UIC).In the proposals that performs a clinical study, it has to be specified in the proposal who is exactly the mandatory member of these dedicated Units.  |
| **Acknowledgements** | Any publication, data base, product or event protected with IPR or not, resulting from the granted project must acknowledge “Award no. XX by Instituto de Salud Carlos III (ISCIII) through AES 2023 and within the ERA4Health Partnership” even after the end of the project, including other specific acknowledgments that could be requested by ISCIII to the granted project. For more information please see ISCIII’s ROR [here](https://ror.org/00ca2c886). |

|  |  |
| --- | --- |
| **Country** | Spain |
| **Funding organisation** | Consejería de Salud y Consumo de la Junta de Andalucía |
| **National contact person** | Alicia Milano CurtoTel: 955040450email convocatorias.fps@juntadeandalucia.es |
| **Funding commitment**  | 250.000,00 € |
| **Anticipated number of fundable proposals**  | 1-2 |
| **Maximum/ Minimum funding per grant awarded to a project partner** | 125.000€, 250.000€ if coordinator (including 21% indirect costs) |
| **Eligibility of partners**  | * Eligible organisation must be Andalusian Non-profit entities registered as Agent of the Andalusian Knowledge System (Registro de Agentes Andaluces del Conocimiento) with research and innovation activity in Biomedicine and Health Sciences, ie: Research managing foundations of the Andalusian Public Health System
* Principal investigators must be linked through a civil servant, statutory or labour relationship with the applicant or performing centre. For Accredited Health Research Institutes (Institutos de Investigación Sanitaria acreditados, IIS), the link may be with any of the public or private law entities that are part of the IIS provided that the entity meets all the specific requirements determined in each action, and, in any case, be personnel assigned to the IIS.
* More than one partner from Andalusia may participate in the same project
* A PI can only participate in one application per call.
* For receiving regional funding, the final funding decision issued by the corresponding program's decision-making body must be accredited
* The duration of the projects shall be determined by the corresponding JTC. In any case, this period shall be stated in the award resolution.
 |
| **Eligibility of costs, types and their caps** | a) Goods and services: consumables, bibliographic material, equipment rentals, software licenses and external services.b) Personnel costs: specifically hired for the project, including salaries, employer Social Security contributions, legally established compensation and other duly justified expenses derived.c) Travel, accommodation and subsistence according to the maximum amounts of compensation for service established in Decree 54/1989, of March 21, on compensation for service of the Junta de Andalucía, exclusively for people who are part of the research group or hired under the funded project. Exceptionally, any expense outside these amounts, or for people other than those listed before, must be authorised by the granting body.d) From the project' second year onwards: Registration fees for congresses or conferences for the presentation and dissemination of the resultse) Publication costsf) Other expenses duly justified and necessary for carrying out the project.g) Indirect costs 21%h) Subcontracting costs: cannot exceed 50% of the funding and need prior authorization from the granting body. Nor Scientific aspects nor the management of the project should be subcontracted.The following are not considered eligible expenses- Equipment or Equipment repair and maintenance - Items or amounts that, after analysis, are not considered justified - Amounts paid to persons participating in the project, with the exception of expenses necessary for special attention to patients that involve compensation for their participation in the project not derived from an employment relationship.The sum of the funding or income received for the same purpose may in no case exceed the cost of the funded activity. |
| **Submission of the proposal at the national level** | * Regional applications must be submitted to the General Secretariat of Public Health and R&D&I in Health exclusively by telematic means.
* The deadline for the submission of regional applications will be established in the regional call and will be informed through the website of the Regional Ministry of Health and Consumer Affairs.
 |
| **Submission of other information at the national level** | The following documents must be provided:* Certificate of registration in the corresponding public registry
* National ID (DNI) of the person legally representing the applicant entity
* Fiscal Identification Code (CIF) of the applicant entity
* Documentation accrediting the representation or power of attorney of the legal representative.
* Certificate of being up to date in the fulfilment of the obligations with the Social Security and tax obligations.
* Statutes
* Documentation accrediting duly compliance with the obligation to submit the accounts to Protectorado de las Fundaciones Andaluzas
* For projects involving invasive procedures on human beings, their biological material and/or clinical data, a favourable report or a document accrediting the request for its evaluation by the Biomedical Research Ethics Committee has to be provided
 |
| **Submission of financial and scientific reports at the national level** | Beneficiaries must submit financial and scientific reports to Consejería de Salud y Consumo de la Junta de Andalucía |
| **Further guidance** | The projects must respect the fundamental principles established in national and international declarations, protocols and conventions on research ethics, as well as respect the requirements established in national and regional legislation in the field of biomedical research, development and innovation, personal data protection and bioethics.When the results are not susceptible to protection of industrial or intellectual property rights, the scientific publications resulting from the funding granted must be made available in open access, in accordance with article 37 of Law 14/2011, of June 1. |

|  |  |
| --- | --- |
| **Country** | Taiwan |
| **Funding organisation** | National Science and Technology Council |
| **National contact person** | Dr. Ching-Mei TangEmail: cmtom@nstc.gov.twTel: +886-2-2737-7557 |
| **Funding commitment**  | 810,000€ |
| **Anticipated number of fundable proposals**  | 2-3 |
| **Maximum/ Minimum funding per grant awarded to a project partner** | -The maximum amount per year per project is €90,000.00 (about NTD3,000,000). -The decision regarding the exact amount of the grant is dependent on the result of the NSTC’s internal reviews. -The number of grants of every principle investigator must comply with NSTC’s regulation of the max number of two international cooperation projects granted by NSTC for the same duration. |
| **Eligibility of partners**  | All research institutes, universities, hospitals, public organisations in Taiwan endorsed by the National Science and Technology Council (NSTC) as eligible institutions |
| **Eligibility of costs, types and their caps** | Including personnel, consumables, hosting expenses for foreign researchers, and travel expenses for international destinations-joint research & overseas studies, for more information please refer to: https://www.nstc.gov.tw/folksonomy/list/f6d5c23c-b3ce-438e-911b-12a705dbac5a?l=ch |
| **Submission of the proposal at the national level** | No official national application is needed in the pre-proposal or full proposal phase. But must notify the national contact person in the National Science and Technology Council of your submission to the ERA4Health joint transnational call via email, together with your application as an attachment. |
| **Submission of other information at the national level** | -Taiwanese project partners shall submit a proposal to the NSTC for national financing after the project has been selected and approved for funding through the ERA4Health evaluation and selection process.-The proposals are required to be submitted to NSTC for funding as soon as possible as the internal process of the NSTC generally takes 6 months. |
| **Submission of financial and scientific reports at the national level** | please refer to: https://www.nstc.gov.tw/folksonomy/list/f6d5c23c-b3ce-438e-911b-12a705dbac5a?l=ch |
| **Further guidance** | https://www.nstc.gov.tw/folksonomy/rfpDetail/c1a582ae-95bc-4449-908f-590d6cb409ea?l=ch |
| **Country** | Türkiye |
| **Funding organisation** | The scientific and technological research council of Türkiye |
| **National contact person** | Şükran Alpdemir |
| **Funding commitment**  | 750 000 Euros |
| **Anticipated number of fundable proposals**  | Around 6 proposals |
| **Maximum/ Minimum funding per grant awarded to a project partner** | 2 500 000 Turkish Liras (TL) (around 130 000 Euros) per project, 1 500 000 TL for public institutions and 2 500 000 TL for private companies with 60% funding of the eligible costs for large companies and 75% funding of the eligible costs for SMEs |
| **Eligibility of partners**  | The funding is granted to Principal Investigators from universities, public or private sector. The PI is subject to eligibility check. The eligibility check is done according to the TUBITAK 1071 Programme regulations and the published national call document. **Eligibility of PIs or other research team members:**    **Project Manager, Researchers and Advisors:**1. University personnel should have a PhD degree.
2. Those working in a public institution or a private corporation should have an undergraduate degree.
3. Except advisors, the project manager and researchers should reside and work in Türkiye.
4. A researcher should have a contribution of at least 10% of the project workload.
5. An advisor is allowed if the project requires special expertise on a specific subject. The number of advisors in a project is limited to the number of specific subjects in the project. The role of advisor in the project should be explained in detail in the project proposal.

NOTE:University rectors and vice rectors, deans, head of academy/institute, surgeons general, general secretaries, general managers, state department heads and members of the executive committee/advisory board of TÜBİTAK groups cannot be the project manager in any project if they are working in those positions as of the application date. However, they can be researchers in at most two projects.Applications are not accepted from foundations, associations and their economic enterprises, cooperatives, unions, sole proprietorships and ordinary partnerships. |
| **Eligibility of costs, types and their caps** |

|  |  |
| --- | --- |
| **Personnel**Up to 3-year (36 months), full-time or part-time contracts (only for additional personnel)  | The relevant terms in the TÜBİTAK 1509 - International Industry R&D Projects Support Programme Implementation Principles document are valid for legal entities from the private sector.Other personnel costs, including scholarships for university students are included in the 1071 Programme regulations and the published national call document. |
| **Small Equipment** | Eligible, must be used for the project |
| **Travel and Allowance** | Eligible, up to 160,000 TL per organization (app 8000 €) |
| **Consumables** | Eligible |
| **Subcontracting and other services** | Eligible |
| **Overheads** | Not eligible, calculated as extra |

Only project meetings and short study visits are eligible, long-term capacity building activities are not eligible for funding from TUBITAK. |
| **Submission of the proposal at the national level** | Yes |
| **Submission of other information at the national level** | Yes |
| **Submission of financial and scientific reports at the national level** | Yes |
| **Further guidance** | Participants from Türkiye should also submit their proposals to TUBITAK electronically via (<https://uidbpbs.tubitak.gov.tr/>) for the pre-proposal phase. Only the PIs from successful projects that are listed for funding after the second stage of international evaluation are required to submit their full proposals. The applications should be completed via e-signature. |

1. <https://ec.europa.eu/info/sites/default/files/research_and_innovation/funding/documents/ec_rtd_he-partnerships-era-for-health.pdf> [↑](#footnote-ref-2)
2. [Cardiovascular diseases (CVDs) (who.int)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-%28cvds%29) [↑](#footnote-ref-3)
3. <https://ehnheart.org/cvd-statistics/cvd-statistics-2017.html> [↑](#footnote-ref-4)
4. <https://ec.europa.eu/research/participants/docs/h2020-funding-guide/cross-cutting-issues/ethics_en.htm> [↑](#footnote-ref-5)
5. <https://journals.plos.org/plosbiology/article/file?id=10.1371/journal.pbio.1000412&type=printable> [↑](#footnote-ref-6)
6. <https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/partner-search> [↑](#footnote-ref-7)
7. https://open-research-europe.ec.europa.eu/ [↑](#footnote-ref-8)
8. https://www.nature.com/articles/sdata201618 [↑](#footnote-ref-9)
9. Last name, first name of the researchers, date of birth, professional contact information, degree(s), position (current and previous), fields of activity, place of work, organisation, address(es), curriculum vitae, ORCID number, name and reference of projects, pre-proposals, project proposals (scientific document, administrative and financial appendix). [↑](#footnote-ref-10)